❌

Reading view

↗️

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

βœ‡Nature Medicine
By: Princess U. Ogbogu Β· Florence Roufosse Β· Praveen Akuthota Β· Piotr Kuna Β· Matthieu Groh Β· Andreas Reiter Β· Akira Yokota Β· Salman H. Siddiqui Β· Pim G. N. J. Mutsaers Β· Bing Li Β· Paneez Khoury Β· Lila M. Bahadori Β· Artur Bednarczyk Β· Gerben Bouma Β· Laura G. Brooks Β· Jorge Ferreira Β· Hanna Grindebacke Β· Calvin N. Ho Β· Priya Jain Β· Rebecca L. Palmer Β· Maria L. Jison Β· Amy D. Klion

Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8

Benralizumab (an anti-IL-5 receptor Ξ± antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.
  •  
  • ↗️
↗️

Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies

βœ‡Cell Death Discovery nature.com science feeds
By: Richmond Kwame Frimpong Asiedu Β· Mahamadou Souley Abdou Β· Rongbin Wei Β· Zhongdang Xiao Β· Bing Li Β· Ming Hu

Cell Death Discovery, Published online: 12 March 2026; doi:10.1038/s41420-026-02996-1

Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies
  •  
  • ↗️
There are no more articles
❌